Back to Cell Types

TTHomo sapiens (Human)Cancer cell line

Also known as: MTC-TT

🤖 AI SummaryBased on 13 publications

TT Cell Line

Quick Overview

Human medullary thyroid carcinoma cell line with RET mutation

Detailed Summary

The TT cell line is a human medullary thyroid carcinoma (MTC) cell line derived from a patient with an aggressive form of the disease. It is characterized by the presence of a heterozygous point mutation in the RET proto-oncogene, specifically a Cys634Trp substitution, which is associated with multiple endocrine neoplasia type 2A (MEN2A). This cell line retains some differentiated features of normal thyroid C-cells, including the production of calcitonin and calcitonin gene-related peptide (CGRP). The TT cell line has been extensively used in research to study the molecular mechanisms of MTC, including the role of RET mutations in tumorigenesis and the development of targeted therapies. It is also utilized in studies related to cell differentiation, signal transduction pathways, and drug screening for potential therapeutic interventions.

Research Applications

Molecular mechanisms of MTCRET mutation analysisDrug screeningSignal transduction pathwaysCell differentiation studies

Key Characteristics

Heterozygous Cys634Trp RET mutationCalcitonin and CGRP productionUsed in MEN2A researchCytogenetic stability

Generated on 6/17/2025

Basic Information

Database ID	CVCL_1774
Species	Homo sapiens (Human)
Tissue Source	Thyroid gland[UBERON:UBERON_0002046]

Donor Information

Age	77
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Familial medullary thyroid carcinoma
Lineage	Thyroid
Subtype	Medullary Thyroid Cancer
OncoTree Code	THME

DepMap Information

Source Type	ATCC
Source ID	ACH-001321_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TBX3	p.Trp197Ter (c.591G>A)	Heterozygous	-	Unknown, Unknown, PubMed=30737244
MutationSimple	RET	p.Cys634Trp (c.1902C>G)	Heterozygous	-	Unknown, Unknown, PubMed=30737244, PubMed=7736432

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10,13

D13S317

11

D16S539

12,13

D18S51

12

D19S433

14,15

D21S11

29,32.2

D2S1338

17,23

D3S1358

15

D5S818

12,13

D7S820

10,12

D8S1179

15,16

FGA

21,25

Penta D

13

Penta E

7,13

TH01

6,9

TPOX

8,11

vWA

16,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

Fagin J.A., Schweppe R.E.

Clin. Cancer Res. 25:3141-3151(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

The role of cell lines in the study of neuroendocrine tumors.";

Grozinsky-Glasberg S., Shimon I., Rubinfeld H.

Neuroendocrinology 96:173-187(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on Ret proto-oncogene activity.

Zhu W., Hai T., Ye L., Cote G.J.

J. Clin. Endocrinol. Metab. 95:439-444(2010).

DNA microarray to monitor the expression of MAGE-A genes.";

Lobert P.-E., Hamels S., Boon T., Remacle J.

Clin. Chem. 48:25-34(2002).

Characterisation of thyroid medullary carcinoma TT cell line.";

Zabel M., Grzeszkowiak J.

Histol. Histopathol. 12:283-289(1997).

Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line.

Panariello L., Colantuoni V., Fusco A.

Biochem. Biophys. Res. Commun. 207:1022-1028(1995).

Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines.

Cooley L.D., Elder F.F.B., Knuth A., Gagel R.F.

Cancer Genet. Cytogenet. 80:138-149(1995).

Cytogenetic studies of a human medullary thyroid carcinoma cell line.

Tanaka K., Baylin S.B., Nelkin B.D., Testa J.R.

Cancer Genet. Cytogenet. 25:27-35(1987).

Characterization and calcitonin secretion of a human well differentiated C-cell tumor cell line.

Kameya T., Kadoya K., Iguchi H.

Hum. Cell 2:231-237(1989).

Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.

Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.

Cancer Res. 52:5061-5064(1992).

Head and neck tumor cell lines.";

Carey T.E.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York; USA (1994).

Web Resources